The SIRSA, SIRveNIB, SARAH and SORAMIC Clinical Trials - ITR8

• Inclusion criteria:
SIRveNIB SARAH
– Bili Bilirubin bi < 2.0 2 0 mg/dL /dL
– Platelets: ≥ 80.000/µL
– Leukocytes ≥ 2.500/µL 2 500/µL
– Albumin ≥ 2.5g/dL
• Exclusion criteria:
– Last loco-regional treatment
min < 4 weeks before study y
entry
– Complete main portal vein
th thrombosis b i
– Prior hepatic radiation therapy
for HCC or other malignancy g y
SGH – Surgery
• Inclusion criteria:
– Bilir Bilirubin bin < 50 µml/L ml/L (2,9 (2 9 mg/dL)
– Platelets ≥ 50.000/mm3